Related Experiment Video
Updated: Sep 26, 2025
Fabrication of 3D Cardiac Microtissue Arrays using Human iPSC-Derived Cardiomyocytes, Cardiac Fibroblasts, and Endothelial Cells
Published on: March 14, 2021
Bioengineering Strategies to Create 3D Cardiac Constructs from Human Induced Pluripotent Stem Cells
Fahimeh Varzideh1,2, Pasquale Mone1, Gaetano Santulli1,2
1Department of Medicine, Wilf Family Cardiovascular Research Institute, Einstein-Mount Sinai Diabetes Research Center (ES-DRC), Einstein Institute for Aging Research, Albert Einstein College of Medicine, New York, NY 10461, USA.
Bioengineering cardiac tissues from human induced pluripotent stem cells (hiPSCs) overcomes the immaturity limitations of current models. These advanced in vitro cardiac tissues offer improved platforms for cardiovascular disease research and drug discovery.
Area of Science:
- Biotechnology
- Cardiovascular Research
- Stem Cell Biology
Background:
- Human induced pluripotent stem cells (hiPSCs) are a versatile source for generating diverse human cell types.
- hiPSC-derived cardiomyocytes (hiPSC-CMs) are valuable for disease modeling, drug testing, and regenerative medicine.
- The immaturity of hiPSC-CMs in 2D cultures restricts their utility.
Purpose of the Study:
- To review recent advances in bioengineering technologies for producing hiPSC-derived cardiac tissues.
- To highlight the potential of advanced in vitro cardiac models for cardiovascular research.
Main Methods:
- Focuses on bioengineering strategies to mature hiPSC-CMs.
- Discusses the creation of contractile cardiac structures and in vitro heart microtissues.
Main Results:
- Bioengineered cardiac tissues exhibit enhanced maturity and functionality compared to traditional 2D cultures.
- These advanced models serve as sophisticated platforms for drug screening and disease simulation.
Conclusions:
- Bioengineering cardiac tissues from hiPSCs represents a significant advancement in creating functional in vitro models.
- These improved models hold promise for accelerating the development of novel treatments for cardiovascular disorders.
